Document Detail

Antiangiogenic therapies in portal hypertension: a breakthrough in hepatology.
MedLine Citation:
PMID:  20630674     Owner:  NLM     Status:  MEDLINE    
Portal hypertension is the most important complication that develops in patients with cirrhosis. Several studies have shown that angiogenesis (i.e. splanchnic neovascularization) driven by VEGF and other proangiogenic molecules, like PDGF, may be a major mechanism involved in portal hypertension, hyperdynamic splanchnic circulation and portosystemic collateralization. According with this, antiangiogenic therapies, like sorafenib or sunitinib, have been recently shown to reduce portosystemic collateral circulation, improve splanchnic hyperdynamics and decrease portal pressure in experimental model of portal hypertension. This effect was associated to a decrease in VEGF, PDGF expression and splanchnic neovascularization. In addition, these therapies were associated with a decrease in both splanchnic and intrahepatic inflammatory infiltrates, in hepatic stellate cell activation and in intrahepatic fibrosis. These data suggest that antiangiogenic therapies may therefore, by limiting liver fibrosis and inflammation in cirrhosis, prevent the occurrence of severe complications, such as portal hypertension and potentially liver cancer.
O Rosmorduc
Related Documents :
1777494 - Occlusion of liver veins (budd-chiari syndrome) in childhood: a case report.
6117144 - Hydrostatic pressure reduces synaptic efficiency by inhibiting transmitter release.
8609814 - Long-term favourable outcome of portal hypertension complicating primary systemic amylo...
2359774 - Dorsal pressure differentially affects patterning of locomotor activity in rats.
8295924 - Effects of time pressure on the phonetic realization of the dutch accent-lending pitch ...
19413684 - High-resolution manometry in clinical practice: utilizing pressure topography to classi...
Publication Detail:
Type:  Journal Article; Review     Date:  2010-07-13
Journal Detail:
Title:  Gastroentérologie clinique et biologique     Volume:  34     ISSN:  2210-7401     ISO Abbreviation:  Gastroenterol. Clin. Biol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-29     Completed Date:  2011-01-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7704825     Medline TA:  Gastroenterol Clin Biol     Country:  France    
Other Details:
Languages:  eng     Pagination:  446-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Masson SAS. All rights reserved.
INSERM UMR-S938, service d'hépatologie, hôpital Saint-Antoine, faculté de médecine Pierre-et-Marie-Curie, université Paris-6, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use*
Anoxia / complications,  etiology
Hypertension, Portal / drug therapy*,  etiology
Liver Cirrhosis / complications*
Neovascularization, Pathologic / drug therapy*,  etiology
Splanchnic Circulation
Reg. No./Substance:
0/Angiogenesis Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  T295M-associated Glut1 deficiency syndrome with normal erythrocyte 3-OMG uptake.
Next Document:  The Perceived long-term impact of the radiological curriculum innovation in the medical doctors trai...